San Diego-primarily based Viking Therapeutics marked itself as a serious competitor in the weight loss drug industry in February just after revealing promising details from a mid-stage demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when provided like a weekly injection As well as in March the